Homocysteine and vascular access thrombosis in hemodialysis patients

Renal Failure

Volumn 24, Issue 2, 2002, Pages 215-222

  Hojs, Radovan ^a   Gorenjak, Maksimiljan ^a   Ekart, Robert ^a   Dvorsak, Benjamin ^a   Pecovnik Balon, Breda ^a  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

End stage renal failure; Hemodialysis; Homocysteine; Vascular access thrombosis

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTERY THROMBOSIS; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASCULAR ACCESS; VEIN THROMBOSIS; BLOOD; CHRONIC KIDNEY FAILURE; INDWELLING CATHETER; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; TIME;

ADULT; AGED; ARTERIOVENOUS FISTULA; CATHETERS, INDWELLING; FEMALE; HOMOCYSTEINE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGE; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; VENOUS THROMBOSIS; HUMANS; MIDDLE AGED;

EID: 0035987766     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120004098     Document Type: Article

References (40)

1. Vascular access thrombosis - What are the possibilities of intervention?
2. Vascular access: Concepts for the 1990s
3. Vascular access thrombosis in new hemodialysis patients
4. NKF-DOQI clinical practice guidelines for vascular access
5. Hemodialysis vascular access morbidity
6. Vascular access survival among incident hemodialysis patients in the United States
7. Prosthetic fistula survival and complications in hemodialysis patients: Effects of diabetes and age
8. Canadian hemodialysis morbidity study
9. Prealbumin and lipoprotein(a) in hemodialysis: Relationships with patient and vascular access survival
10. Lipids abnormalities - Risk factor for hemodialysis vascular access thrombosis?
11. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis
12. Antiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis
13. Plasma thrombomodulin: Usefulness as a blood access failure marker in hemodialysis patients
14. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis
15. Is hyperhomocystinemia a risk factor for recurrent venous thrombosis?
16. Hyperhomocysteinemia: An independent risk factor for vascular disease
17. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
18. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis
19. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes
20. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
21. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis
22. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
23. Homocysteinemia and vascular disease in end-stage renal disease
24. Homocysteine and heart disease in dialysis patients
25. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study
26. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
27. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?
28. Plasma homocysteine in renal failure
29. Homocyst(e)ine and vascular access complications in haemodialysis patients: Insights into a complex metabolic relationship
30. Sulphur containing amino acids in chronic renal failure with particular references to homocysteine and cysteine-homocysteine mixed disulphide
31. 12 and folic acid in end-stage renal disease during low dose supplementation with folic acid
32. The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients
33. Serum total homocysteine concentrations before and after renal transplantation
34. Hyperhomocystinemia, hyperfibrinogenemia and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study
35. Prevalence of moderate hyperhomocystinemia in patients with early-onset venous and arterial occlusive disease
36. Hyperhomocystinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients
37. Homocysteine, B vitamins, and vascular access thrombosis in patients treated with hemodialysis
38. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study
39. Is hyperhomocystinemia a risk factor for recurrent vascular access thrombosis in hemodialysis patients?
40. Hyperhomocystinemia and thrombosis: Acquired conditions